SlideShare a Scribd company logo
1 of 9
Download to read offline
Summary and Discussion Points for Pharmacokinetic (Category2)
& Clinical Abuse Potential Studies (Category3)
Kerri A Schoedel, PhD
Director and Principal
Altreos Research Partners, Inc.
INC Research Consultant

On behalf of Ed Sellers

Abuse Deterrent Formulation Science Meeting
Sep 30-Oct 1, 2013
FDA Guidance: Conceptual Framework for Evaluation

FDA considers the development of these products a high public health priority.

…the extent to which an abuse-deterrent product is able to reduce abuse will
never be absolute.

…FDA will take a flexible, adaptive approach to the evaluation and labeling of
potentially abuse-deterrent products
2
Pharmacokinetics: Category 2
• Silvia’s Questions:

• What is the impact of the rate of rise, which may contribute to differential
abuse potential among drugs, formulations, and routes of administration?
• Is it possible to predict clinical abuse potential study results based on
different pharmacokinetic profiles between formulations?

Panel Recommendations
Pharmacokinetic parameters such as Cmax, Tmax and AUC will nearly always need
to be evaluated in the context of pharmacodynamic outcomes
•
•

Particularly for intranasal studies
Possible exception of oral study where PK of tampered is identical to PK of intact (for simple
physical barrier formulation)

Pharmacokinetic data alone can answer questions about BE/BA, food effects ,
alcohol interactions
3
Subject Selection and Qualification
• Do the following influence subject selection?

• Dose or doses of the test drug
• Range of doses of the test drug
• Setting or establishment of an appropriate placebo response

Use of same (or intermediate dose) in Qualification appears to have
advantages over use of a lower dose
• Lower dose may result in plateau effects, increased dropouts and select
for a less relevant population
• Subject eligibility criteria should attempt to strike balance between Type I
and Type II errors (e.g., 2 doses vs. 1 dose in qualification)
4
Blinding and Manipulation
• How can we improve blinding?
• Is it acceptable to encapsulate crushed product that can not be taken into a
solution?
• Lack of public data on appropriate manipulation techniques
• Blinding should be undertaken, but not to extent that it obliterates the
features of the formulation you are trying to assess in the study
• (Encapsulation may be acceptable but should generally be last resort:
• use of alternative vehicles (tomato juice? Apple sauce?) or placebo
solution manipulations (flour in placebo solution?) preferable)

5
Measures and Interpretation
• Measures
• Does it make a difference if measures are taken in a unipolar or a bipolar
scale(s)?

• Primary measures of Drug Liking should be bipolar for most cases
•

Unipolar measures such as Good and Bad Effects important for interpretation

• Over reliance on Emax may increase risk of false negative
• Consider whole profile of effects and in particular end-of-day/next-day measures of Overall
Liking and Take Drug Again
• Derived endpoints evaluating time course profile important for interpretation
• Value of open-ended feedback or development standardized follow-up questions?
6
Interpretation and CID
• Interpretation of results

• What constitutes a clinically significant difference in drug liking between the test
drug and positive controls?

Insufficient data currently available to support pre-specifying δ1 super superiority margin
• δ1 must be based on scientific/regulatory consensus
• Sufficient data to pre-specify δ2 (PBO-Control) but probably not needed

• Interpretation of clinical relevance should consider whole profile of effects → Convergence of data
• Make use of anchors on bipolar scales – Strong liking/disliking vs. Neutral
• Make better use of other arms within the study (e.g., PBO vs. Test; intact arm in oral study, oral
arm in IN study) or add additional comparisons → preferable to adding multiple doses
• (Start to consider how we may develop non-inferiority/equivalence margins in comparison to
existing ADFs?)
7
Statistics
• Statistical analysis
• What is the best approach?

Recommendations for statistical analysis relatively clear
•

Data may require non-parametric methods not mentioned in guidance

Use of responder analysis to arbitrarily convert continuous Drug Liking variable
into categorical variable
•
•

Potential loss of power
Interpretability, i.e., assumptions of clinically relevant margins X 2 (% of subjects and %
decrease in Liking)

Data presentations must consider the end-users of the labels (prescribers)
• Data presentation should be familiar and easy to understand
8
Opioid Naïve
Individuals

Opioid Dependent
Abusers

Recreational users

Pain Patients
Occasional
users

Acute pain
patient
Chronic pain
patient

Moderate
users
Heavy
users
Non-treatment
seeking

Patient abuser

In treatment
(eg, methadone)

Oral users
Tamperers

Misusers

Intranasal users
Intravenous users
Not addressed in Guidance
Not much literature

Current Methods
Addressed in Guidance

Not addressed in Guidance
9
Scientific Literature

More Related Content

What's hot

Systematic reviews of adverse effects and other topics not – yet – covered by...
Systematic reviews of adverse effects and other topics not – yet – covered by...Systematic reviews of adverse effects and other topics not – yet – covered by...
Systematic reviews of adverse effects and other topics not – yet – covered by...Cochrane.Collaboration
 
Statistical outliers in BE Studies DIA 12 april 2019
Statistical outliers in BE Studies DIA 12 april 2019Statistical outliers in BE Studies DIA 12 april 2019
Statistical outliers in BE Studies DIA 12 april 2019Bhaswat Chakraborty
 
Meta Analysis of Medical Device Data Applications for Designing Studies and R...
Meta Analysis of Medical Device Data Applications for Designing Studies and R...Meta Analysis of Medical Device Data Applications for Designing Studies and R...
Meta Analysis of Medical Device Data Applications for Designing Studies and R...NAMSA
 
Non inferiority trials: any advantage for patients?
Non inferiority trials: any advantage for patients?Non inferiority trials: any advantage for patients?
Non inferiority trials: any advantage for patients?Cochrane.Collaboration
 
Ich guidelines e9 to e12
Ich guidelines e9 to e12Ich guidelines e9 to e12
Ich guidelines e9 to e12Khushboo Bhatia
 
Superiority, non-inferiority, equivalence studies - what is the difference?
Superiority, non-inferiority, equivalence studies - what is the difference?Superiority, non-inferiority, equivalence studies - what is the difference?
Superiority, non-inferiority, equivalence studies - what is the difference?simonledinek
 
Simplifying study designs and statistical models for new dose & dosage forms ...
Simplifying study designs and statistical models for new dose & dosage forms ...Simplifying study designs and statistical models for new dose & dosage forms ...
Simplifying study designs and statistical models for new dose & dosage forms ...Bhaswat Chakraborty
 
Learning about drug use problem
Learning about drug use problemLearning about drug use problem
Learning about drug use problemSohani Ali
 
Overview Of Ich New E9
Overview Of Ich New E9Overview Of Ich New E9
Overview Of Ich New E9Jay1818mar
 
Pharm d research project
Pharm d research projectPharm d research project
Pharm d research projectSai Kumar
 
Randomized clinical trials
Randomized clinical trialsRandomized clinical trials
Randomized clinical trialsAhmed Nouri
 
Beyond Traditional Designs in Early Drug Development
Beyond Traditional Designs in Early Drug DevelopmentBeyond Traditional Designs in Early Drug Development
Beyond Traditional Designs in Early Drug DevelopmentMaRS Discovery District
 
# 9th lect clinical trial analysis
# 9th lect  clinical  trial analysis# 9th lect  clinical  trial analysis
# 9th lect clinical trial analysisDr. Eman M. Mortada
 
Adaptive Study Designs
Adaptive Study DesignsAdaptive Study Designs
Adaptive Study DesignsAnirudha Potey
 
EBM Systematic Review Appraisal Template V1
EBM Systematic Review Appraisal Template V1EBM Systematic Review Appraisal Template V1
EBM Systematic Review Appraisal Template V1Imad Hassan
 
Importance of clinical trials in drug discovery
Importance of clinical trials in drug discoveryImportance of clinical trials in drug discovery
Importance of clinical trials in drug discoveryKarunaMane1
 
Choice of control group in clinical trials
Choice of control group in clinical trialsChoice of control group in clinical trials
Choice of control group in clinical trialsNagendra SR
 

What's hot (20)

Systematic reviews of adverse effects and other topics not – yet – covered by...
Systematic reviews of adverse effects and other topics not – yet – covered by...Systematic reviews of adverse effects and other topics not – yet – covered by...
Systematic reviews of adverse effects and other topics not – yet – covered by...
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
 
Statistical outliers in BE Studies DIA 12 april 2019
Statistical outliers in BE Studies DIA 12 april 2019Statistical outliers in BE Studies DIA 12 april 2019
Statistical outliers in BE Studies DIA 12 april 2019
 
Meta Analysis of Medical Device Data Applications for Designing Studies and R...
Meta Analysis of Medical Device Data Applications for Designing Studies and R...Meta Analysis of Medical Device Data Applications for Designing Studies and R...
Meta Analysis of Medical Device Data Applications for Designing Studies and R...
 
Non inferiority trials: any advantage for patients?
Non inferiority trials: any advantage for patients?Non inferiority trials: any advantage for patients?
Non inferiority trials: any advantage for patients?
 
Ich guidelines e9 to e12
Ich guidelines e9 to e12Ich guidelines e9 to e12
Ich guidelines e9 to e12
 
Superiority, non-inferiority, equivalence studies - what is the difference?
Superiority, non-inferiority, equivalence studies - what is the difference?Superiority, non-inferiority, equivalence studies - what is the difference?
Superiority, non-inferiority, equivalence studies - what is the difference?
 
Simplifying study designs and statistical models for new dose & dosage forms ...
Simplifying study designs and statistical models for new dose & dosage forms ...Simplifying study designs and statistical models for new dose & dosage forms ...
Simplifying study designs and statistical models for new dose & dosage forms ...
 
Learning about drug use problem
Learning about drug use problemLearning about drug use problem
Learning about drug use problem
 
Designs of clinical trials
Designs of clinical trialsDesigns of clinical trials
Designs of clinical trials
 
Overview Of Ich New E9
Overview Of Ich New E9Overview Of Ich New E9
Overview Of Ich New E9
 
Pharm d research project
Pharm d research projectPharm d research project
Pharm d research project
 
Randomized clinical trials
Randomized clinical trialsRandomized clinical trials
Randomized clinical trials
 
Beyond Traditional Designs in Early Drug Development
Beyond Traditional Designs in Early Drug DevelopmentBeyond Traditional Designs in Early Drug Development
Beyond Traditional Designs in Early Drug Development
 
# 9th lect clinical trial analysis
# 9th lect  clinical  trial analysis# 9th lect  clinical  trial analysis
# 9th lect clinical trial analysis
 
Adaptive Study Designs
Adaptive Study DesignsAdaptive Study Designs
Adaptive Study Designs
 
EBM Systematic Review Appraisal Template V1
EBM Systematic Review Appraisal Template V1EBM Systematic Review Appraisal Template V1
EBM Systematic Review Appraisal Template V1
 
Importance of clinical trials in drug discovery
Importance of clinical trials in drug discoveryImportance of clinical trials in drug discovery
Importance of clinical trials in drug discovery
 
Choice of control group in clinical trials
Choice of control group in clinical trialsChoice of control group in clinical trials
Choice of control group in clinical trials
 
Drug development process
Drug development processDrug development process
Drug development process
 

Similar to Summary and Discussion Points for Pharmacokinetic (Category2) & Clinical Abuse Potential Studies (Category3)

Definition and scope of Pharmacoepidemiology
Definition and scope of Pharmacoepidemiology Definition and scope of Pharmacoepidemiology
Definition and scope of Pharmacoepidemiology ABUBAKRANSARI2
 
Non Randomised Control Trial
Non Randomised Control TrialNon Randomised Control Trial
Non Randomised Control TrialKarishma Halageri
 
Clinical Trials_1_Fundamentals_Randomised Clinical Trials.pptx
Clinical Trials_1_Fundamentals_Randomised Clinical Trials.pptxClinical Trials_1_Fundamentals_Randomised Clinical Trials.pptx
Clinical Trials_1_Fundamentals_Randomised Clinical Trials.pptxVijay Rathod
 
phase 1 clinical trial
phase 1 clinical trialphase 1 clinical trial
phase 1 clinical trialJyoti Sharma
 
Drug Utilization Studies
Drug Utilization StudiesDrug Utilization Studies
Drug Utilization StudiesVedvyasMishra1
 
ich guidelines for clinical trials, scientific approach ppt.pptx
ich guidelines for clinical trials, scientific approach ppt.pptxich guidelines for clinical trials, scientific approach ppt.pptx
ich guidelines for clinical trials, scientific approach ppt.pptxJyotshnaDevi4
 
FDA 2013 Clinical Investigator Training Course: The Design of Clinical Trials
FDA 2013 Clinical Investigator Training Course: The Design of Clinical Trials FDA 2013 Clinical Investigator Training Course: The Design of Clinical Trials
FDA 2013 Clinical Investigator Training Course: The Design of Clinical Trials MedicReS
 
Role of clinical trials in drug discovery &
Role of clinical trials in drug discovery &Role of clinical trials in drug discovery &
Role of clinical trials in drug discovery &Bhaswat Chakraborty
 
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)Anjali Rarichan
 
6. Randomised controlled trial
6. Randomised controlled trial6. Randomised controlled trial
6. Randomised controlled trialRazif Shahril
 
FDA 2013 Clinical Investigator Training Course: Clinical Trial Endpoints
FDA 2013 Clinical Investigator Training Course: Clinical Trial EndpointsFDA 2013 Clinical Investigator Training Course: Clinical Trial Endpoints
FDA 2013 Clinical Investigator Training Course: Clinical Trial EndpointsMedicReS
 

Similar to Summary and Discussion Points for Pharmacokinetic (Category2) & Clinical Abuse Potential Studies (Category3) (20)

Definition and scope of Pharmacoepidemiology
Definition and scope of Pharmacoepidemiology Definition and scope of Pharmacoepidemiology
Definition and scope of Pharmacoepidemiology
 
EOP.SOJA.S5
EOP.SOJA.S5EOP.SOJA.S5
EOP.SOJA.S5
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
 
Non Randomised Control Trial
Non Randomised Control TrialNon Randomised Control Trial
Non Randomised Control Trial
 
Clinical Trials_1_Fundamentals_Randomised Clinical Trials.pptx
Clinical Trials_1_Fundamentals_Randomised Clinical Trials.pptxClinical Trials_1_Fundamentals_Randomised Clinical Trials.pptx
Clinical Trials_1_Fundamentals_Randomised Clinical Trials.pptx
 
phase 1 clinical trial
phase 1 clinical trialphase 1 clinical trial
phase 1 clinical trial
 
Drug Utilization Studies
Drug Utilization StudiesDrug Utilization Studies
Drug Utilization Studies
 
Extrapolation.pptx
Extrapolation.pptxExtrapolation.pptx
Extrapolation.pptx
 
Bioequivalence Studies
Bioequivalence StudiesBioequivalence Studies
Bioequivalence Studies
 
Bioequivalence studies
Bioequivalence studiesBioequivalence studies
Bioequivalence studies
 
ich guidelines for clinical trials, scientific approach ppt.pptx
ich guidelines for clinical trials, scientific approach ppt.pptxich guidelines for clinical trials, scientific approach ppt.pptx
ich guidelines for clinical trials, scientific approach ppt.pptx
 
FDA 2013 Clinical Investigator Training Course: The Design of Clinical Trials
FDA 2013 Clinical Investigator Training Course: The Design of Clinical Trials FDA 2013 Clinical Investigator Training Course: The Design of Clinical Trials
FDA 2013 Clinical Investigator Training Course: The Design of Clinical Trials
 
Role of clinical trials in drug discovery &
Role of clinical trials in drug discovery &Role of clinical trials in drug discovery &
Role of clinical trials in drug discovery &
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiology
 
E4 Presentation.pptx
E4 Presentation.pptxE4 Presentation.pptx
E4 Presentation.pptx
 
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)
 
Microdosing (Phase 0) studies
Microdosing (Phase 0) studiesMicrodosing (Phase 0) studies
Microdosing (Phase 0) studies
 
Clinical Trial phases.pptx
Clinical Trial phases.pptxClinical Trial phases.pptx
Clinical Trial phases.pptx
 
6. Randomised controlled trial
6. Randomised controlled trial6. Randomised controlled trial
6. Randomised controlled trial
 
FDA 2013 Clinical Investigator Training Course: Clinical Trial Endpoints
FDA 2013 Clinical Investigator Training Course: Clinical Trial EndpointsFDA 2013 Clinical Investigator Training Course: Clinical Trial Endpoints
FDA 2013 Clinical Investigator Training Course: Clinical Trial Endpoints
 

Recently uploaded

Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 

Recently uploaded (20)

Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 

Summary and Discussion Points for Pharmacokinetic (Category2) & Clinical Abuse Potential Studies (Category3)

  • 1. Summary and Discussion Points for Pharmacokinetic (Category2) & Clinical Abuse Potential Studies (Category3) Kerri A Schoedel, PhD Director and Principal Altreos Research Partners, Inc. INC Research Consultant On behalf of Ed Sellers Abuse Deterrent Formulation Science Meeting Sep 30-Oct 1, 2013
  • 2. FDA Guidance: Conceptual Framework for Evaluation FDA considers the development of these products a high public health priority. …the extent to which an abuse-deterrent product is able to reduce abuse will never be absolute. …FDA will take a flexible, adaptive approach to the evaluation and labeling of potentially abuse-deterrent products 2
  • 3. Pharmacokinetics: Category 2 • Silvia’s Questions: • What is the impact of the rate of rise, which may contribute to differential abuse potential among drugs, formulations, and routes of administration? • Is it possible to predict clinical abuse potential study results based on different pharmacokinetic profiles between formulations? Panel Recommendations Pharmacokinetic parameters such as Cmax, Tmax and AUC will nearly always need to be evaluated in the context of pharmacodynamic outcomes • • Particularly for intranasal studies Possible exception of oral study where PK of tampered is identical to PK of intact (for simple physical barrier formulation) Pharmacokinetic data alone can answer questions about BE/BA, food effects , alcohol interactions 3
  • 4. Subject Selection and Qualification • Do the following influence subject selection? • Dose or doses of the test drug • Range of doses of the test drug • Setting or establishment of an appropriate placebo response Use of same (or intermediate dose) in Qualification appears to have advantages over use of a lower dose • Lower dose may result in plateau effects, increased dropouts and select for a less relevant population • Subject eligibility criteria should attempt to strike balance between Type I and Type II errors (e.g., 2 doses vs. 1 dose in qualification) 4
  • 5. Blinding and Manipulation • How can we improve blinding? • Is it acceptable to encapsulate crushed product that can not be taken into a solution? • Lack of public data on appropriate manipulation techniques • Blinding should be undertaken, but not to extent that it obliterates the features of the formulation you are trying to assess in the study • (Encapsulation may be acceptable but should generally be last resort: • use of alternative vehicles (tomato juice? Apple sauce?) or placebo solution manipulations (flour in placebo solution?) preferable) 5
  • 6. Measures and Interpretation • Measures • Does it make a difference if measures are taken in a unipolar or a bipolar scale(s)? • Primary measures of Drug Liking should be bipolar for most cases • Unipolar measures such as Good and Bad Effects important for interpretation • Over reliance on Emax may increase risk of false negative • Consider whole profile of effects and in particular end-of-day/next-day measures of Overall Liking and Take Drug Again • Derived endpoints evaluating time course profile important for interpretation • Value of open-ended feedback or development standardized follow-up questions? 6
  • 7. Interpretation and CID • Interpretation of results • What constitutes a clinically significant difference in drug liking between the test drug and positive controls? Insufficient data currently available to support pre-specifying δ1 super superiority margin • δ1 must be based on scientific/regulatory consensus • Sufficient data to pre-specify δ2 (PBO-Control) but probably not needed • Interpretation of clinical relevance should consider whole profile of effects → Convergence of data • Make use of anchors on bipolar scales – Strong liking/disliking vs. Neutral • Make better use of other arms within the study (e.g., PBO vs. Test; intact arm in oral study, oral arm in IN study) or add additional comparisons → preferable to adding multiple doses • (Start to consider how we may develop non-inferiority/equivalence margins in comparison to existing ADFs?) 7
  • 8. Statistics • Statistical analysis • What is the best approach? Recommendations for statistical analysis relatively clear • Data may require non-parametric methods not mentioned in guidance Use of responder analysis to arbitrarily convert continuous Drug Liking variable into categorical variable • • Potential loss of power Interpretability, i.e., assumptions of clinically relevant margins X 2 (% of subjects and % decrease in Liking) Data presentations must consider the end-users of the labels (prescribers) • Data presentation should be familiar and easy to understand 8
  • 9. Opioid Naïve Individuals Opioid Dependent Abusers Recreational users Pain Patients Occasional users Acute pain patient Chronic pain patient Moderate users Heavy users Non-treatment seeking Patient abuser In treatment (eg, methadone) Oral users Tamperers Misusers Intranasal users Intravenous users Not addressed in Guidance Not much literature Current Methods Addressed in Guidance Not addressed in Guidance 9 Scientific Literature